SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddys Lab reports Profit after tax of Rs 3115.00 Mln, in the March 2021 quarter

14 May 2021 Evaluate
The March 2021 quarter revenue stood at Rs. 33507.00 millions, up 17.50% as compared to Rs. 28517.00 millions during the corresponding quarter last year.The Net Profit of the company slipped to Rs. 3115.00 millions from Rs. 5028.00 millions, a decline of -38.05% on QoQ basis.The company reported a good operating profit of 6845.00 millions compared to 6482.00 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202103 202003 % Var 202103 202003 % Var 202103 202003 % Var
Sales 33507.00 28517.00 17.50 133491.00 118504.00 12.65 133491.00 118504.00 12.65
Other Income 816.00 1274.00 -35.95 8011.00 7432.00 7.79 8011.00 7432.00 7.79
PBIDT 6845.00 6482.00 5.60 39529.00 36128.00 9.41 39529.00 36128.00 9.41
Interest 169.00 118.00 43.22 467.00 478.00 -2.30 467.00 478.00 -2.30
PBDT 6676.00 6364.00 4.90 39062.00 35650.00 9.57 39062.00 35650.00 9.57
Depreciation 2107.00 1923.00 9.57 8500.00 7892.00 7.70 8500.00 7892.00 7.70
PBT 4569.00 4441.00 2.88 30562.00 27758.00 10.10 30562.00 27758.00 10.10
TAX 1454.00 -587.00 -347.70 8698.00 -1619.00 -637.25 8698.00 -1619.00 -637.25
Deferred Tax 666.00 -1277.00 -152.15 3297.00 -6458.00 -151.05 3297.00 -6458.00 -151.05
PAT 3115.00 5028.00 -38.05 21864.00 29377.00 -25.57 21864.00 29377.00 -25.57
Equity 832.00 831.00 0.12 832.00 831.00 0.12 832.00 831.00 0.12
PBIDTM(%) 20.43 22.73 -10.13 29.61 30.49 -2.87 29.61 30.49 -2.87

Dr. Reddys Labs. Share Price

1356.85 -19.45 (-1.41%)
30-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.70
Dr. Reddys Labs. 1356.85
Cipla 1465.15
Zydus Lifesciences 1112.20
Lupin 2420.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: